In a research report published Friday, Brean Capital analyst Difei Yang maintained a Buy rating on Osiris Therapeutics, Inc. (NASDAQ:OSIR) with a $19.
In a research report sent to investors today, Brean Capital analyst Difei Yang maintained a Buy rating on Osiris Therapeutics (NASDAQ:OSIR) with a …
Osiris Therapeutics (NASDAQ:OSIR) stem cells aren’t the big source of buzz they were just a few years ago. We have moved on to …